The New Playbook: What will define winning FR&D teams in 2030?

Panellists in this video: • Mr Suresh Pareek, Angel and Growth Investor (Pharma) (Moderator) • Dr Sumedha Nadkar, Pharmaceutical Strategy and Technology Consultant • Dr Manish Grover, Director, Healthcare Technologies, Mangrove Creations Key Highlights: [1] Innovation is accelerating through AI, advanced drug delivery, and emerging biopharma players, making bold investment in R&D more critical than ever. [2] A formulation succeeds only when it reaches the patient; patient impact remains the true measure of innovation. [3] In a world of rapid change, technical expertise alone is not enough. Critical thinking, interpretation, and continuous learning are becoming essential skills. [4] AI can accelerate discovery and decision-making, but human judgment, scientific understanding, and cross-cultural collaboration remain irreplaceable. [5] The scientists who stand out will be those who can simplify complexity, communicate beyond scientific jargon, and connect their work to the larger business and patient impact. [6] Innovation needs a bridge between science and business. Sustainable growth comes from balancing scientific excellence with commercial value and profitability. The post The New Playbook: What will define winning FR&D teams in 2030? appeared first on Express Pharma.